Navigation Links
Omeros Announces Positive OMS721 Data in Model of Age-Related Macular Degeneration
Date:11/5/2013

SEATTLE, Nov. 5, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in a well-established animal model of neovascular age-related macular degeneration (AMD), which is characterized by abnormal growth of new blood vessels behind the retina of the eye and is a leading cause of vision loss in individuals over 60 years of age. Omeros is currently completing a Phase 1 clinical trial of OMS721 in healthy subjects.

The study was conducted by Dr. Puran S. Bora and colleagues at the Jones Eye Institute, Pat and Willard Walker Eye Research Center of the University of Arkansas for Medical Sciences. In this animal model, new vessel growth in the eye is induced by laser treatment. Systemically administered OMS721 resulted in less than half of the blood vessel development compared to placebo treatment. The study included an antibody to vascular endothelial growth factor (VEGF) that also reduced blood vessel growth, and OMS721 outperformed the anti-VEGF treatment. Anti-VEGF treatment is the current mainstay of commercially available therapies for neovascular AMD.

Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein involved in activation of the complement system – an important component of the immune system. The complement system plays a role in the inflammatory response to tissue damage or microbial infection, and both human genetic and animal studies have linked the complement system to AMD development. OMS721 selectively inhibits MASP-2, blocking the lectin pathway of the complement system while leaving intact the classical pathway, or the acquired immune response to infection. Omeros recent
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Grants Orphan Drug Designation to Omeros OMS824 for Huntingtons Disease
2. Omeros Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference
3. Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
4. Omeros Reports Additional Positive Results from OMS824 Program
5. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
6. Omeros to Present at the Stifel Healthcare Conference 2013
7. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
8. Omeros Corporation Reports Second Quarter 2013 Financial Results
9. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
10. Omeros Submits New Drug Application to U.S. FDA for OMS302
11. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Investor-Edge has initiated coverage on the following equities: Zogenix ... (NYSE: LLY ), Nektar Therapeutics (NASDAQ: ... AG (NYSE: NVS ). Free research on these ... On Friday, December 12, 2014, the NASDAQ Composite ended ... 1.79%, to finish the day at 17,280.83, and the S&P ...
(Date:12/15/2014)... MINNEAPOLIS , Dec. 15, 2014   ... ), one of the nation,s largest and most ... of its business units, DaVita Clinical Research ... capabilities to further expand its extensive clinical research ... chronic kidney disease (CKD) and end-stage renal disease ...
(Date:12/14/2014)... GREENVILLE, S.C. , Dec. 14, 2014  ChartSpan, ... become the most downloaded iPhone and iPad medical app ... Photo - http://photos.prnewswire.com/prnh/20141214/164317 ... with the ability to request, manage and send electronic ... of innovative entrepreneurs who grew tired of waiting for ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4ChartSpan Becomes The Most Downloaded Medical App in America 2ChartSpan Becomes The Most Downloaded Medical App in America 3
... DIEGO, April 5, 2011 RESMED INC. (NYSE: ... it will release its results for the third quarter and ... A press release with ResMed,s results will be issued after ... conference call and webcast to review its results, market trends, ...
... WOONSOCKET, R.I., April 5, 2011 CVS Caremark ... reputable companies in the United States, according to ... by Forbes magazine in partnership with the Reputation ... the 150 companies included in the survey, CVS ...
Cached Medicine Technology:ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2011 Results 2CVS Caremark Named One of America's Most Reputable Companies by Reputation Institute 2
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
(Date:12/17/2014)... FL (PRWEB) December 17, 2014 No ... not been able to eradicate the head louse parasite—a ... hassle for parents. Each year between six and twelve ... Troopers, the Miami-based lice removal treatment company comes to ... non-toxic and environmentally friendly. With its track record of ...
(Date:12/17/2014)... parents should leave prenatal picture-taking to medical professionals, the ... ultrasound imaging and heartbeat monitors to get "keepsake" images ... "Although there is a lack of evidence ... monitors, prudent use of these devices by trained health ... engineer, said in an agency news release. "Ultrasound ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 2014 South Florida’s leading urgent care provider, ... be a daze of hassle, hustle, and bustle that can ... halls, to burns when making special meals and heartburn after ... happen at any time. To prevent this season of joy ... a list of helpful and healthful holiday tips to keep ...
Breaking Medicine News(10 mins):Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3
... Pharmac decided to fund for the new once-a-day insulin for those ... ,It has decided to give Insulin Glargine or Lantus at a ... is the president for the Diabetes New Zealand said that they ... ,He also said that the insulin would not be ...
... abuse, harassment and violence have become a way of life ... the name of combating Maoist guerrillas, say child rights activists ... umbrella of 36 rights organisations, says it has been urging ... withdraw security forces from all occupied schools but to no ...
... rare form of mosquito-transmitted viral fever//, has claimed two ... the disease, health officials said. ,The disease, which ... time, reportedly entered the state through villages in Betul ... which gives a stooped posture to the victim as ...
... is a great activity with tremendous health and psychological benefits ... say orthopaedic experts. ,The common perception is that sand, ... easier and safer on the joints. But physicians warn that ... ,"As you run on irregular, inconsistent surface like ...
... to live long, research suggests.Two researchers, from the University of Chicago's ... the age at which a mother gives birth has a major ... Gavrilov and Natalia Gavrilova reported that the chances of being alive ... double for a child born to a woman below the age ...
... for approving NHS treatments has been accused of placing ... of an anti-cancer drug. <BR.,Patients suffering from cancer linked ... whose scientific name is pemetrexed disodium, after ... Clinical Excellence (NICE). ,The group analyzed the cost ...
Cached Medicine News:Health News:Girl Students Sexually Harassed by Security Forces in Nepal 2
...
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
Medicine Products: